Special biological issues in the management of women with schizophrenia

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th Edition TR (DSM-IV-TR). American Psychiatric Association, DC, USA (2000).
   Google Scholar
• Riecher-Rössler A, Kulkarni J. Estrogens and gonadal function in schizophrenia and related psychoses. Curr. Top. Behav. Neurosci. 8, 155–171 (2011).
   PubMedGoogle Scholar
• Kraepelin E. Dementia praecox and paraphrenia. In: Psychiatrie: Ein Lehrbuch fur Studierende und Artze. JA Barth, Leipzig, Germany (1893).
   Google Scholar
• Markham JA. Sex steroids and schizophrenia. Rev. Endocr. Metab. Disord. doi:10.1007/s11154-011-9184-2 (2011) (Epub ahead of print).
   Google Scholar
• Perälä J, Suvisaari J, Saarni SI et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 64(1), 19–28 (2007).
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 30, 67–76 (2008).
   PubMed Web of Science ®Google Scholar
• Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch. Gen. Psychiatry 60(6), 565–571 (2003).
   PubMed Web of Science ®Google Scholar
• McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2, 13 (2004).
   PubMed Web of Science ®Google Scholar
• McGrath JJ. The surprisingly rich contours of schizophrenia epidemiology. Arch. Gen. Psychiatry 64(1), 14–16 (2007).
   PubMed Web of Science ®Google Scholar
• Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology 28(Suppl. 2), 17–54 (2003).
   PubMed Web of Science ®Google Scholar
• Seeman MV. The role of estrogen in schizophrenia. J. Psychiatry Neurosci. 21(2), 123–127 (1996).
   PubMed Web of Science ®Google Scholar
• DeLisi LE. The significance of age of onset for schizophrenia. Schizophr. Bull. 18(2), 209–215 (1992).
   PubMed Web of Science ®Google Scholar
• Drake RJ, Addington J, Viswanathan A, Lewis SW, Abel KM. How do age and gender interact as determinants of the incidence and course of non-affective psychosis? Acta Psychiatr. Scand. (2012) (In Press).
   Google Scholar
• Häfner H, Nowotny B, Löffler W, an der Heiden W, Maurer K. When and how does schizophrenia produce social deficits? Eur. Arch. Psychiatry Clin. Neurosci. 246(1), 17–28 (1995).
   PubMed Web of Science ®Google Scholar
• Häfner H, Löffler W, Maurer K, Hambrecht M, an der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr. Scand. 100(2), 105–118 (1999).
   PubMed Web of Science ®Google Scholar
• Cotton SM, Lambert M, Schimmelmann BG et al. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr. Res. 114(1–3), 17–24 (2009).
   PubMed Web of Science ®Google Scholar
• Castle DJ, Wessely S, Murray RM. Sex and schizophrenia: effects of diagnostic stringency, and associations with and premorbid variables. Br. J. Psychiatry 162, 658–664 (1993).
   PubMed Web of Science ®Google Scholar
• Goldstein JM, Link BG. Gender and the expression of schizophrenia. J. Psychiatr. Res. 22(2), 141–155 (1988).
   PubMed Web of Science ®Google Scholar
• Morgan VA, Castle DJ, Jablensky AV. Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian National Study of Low Prevalence (Psychotic) Disorders. Aust. NZ J. Psychiatry 42(1), 74–82 (2008).
   PubMed Web of Science ®Google Scholar
• Opjordsmoen S. Long-term clinical outcome of schizophrenia with special reference to gender differences. Acta Psychiatr. Scand. 83(4), 307–313 (1991).
   PubMed Web of Science ®Google Scholar
• Riecher-Rössler A, Seeman MV. Oestrogens and schizophrenia – introduction. Arch. Womens. Ment. Health 5(3), 91–92 (2002).
   PubMedGoogle Scholar
• Boyce P, Barriball E. Puerperal psychosis. Arch. Womens. Ment. Health 13(1), 45–47 (2010).
   PubMedGoogle Scholar
• Riecher-Rössler A. Oestrogen effects in schizophrenia and their potential therapeutic implications – review. Arch. Womens. Ment. Health 5(3), 111–118 (2002).
   PubMedGoogle Scholar
• Krafft-Ebing G. Untersuchungen uüber Irresein zur Zeit der Menstruation: ein klinischer Beitrag zur Lehre vom periodischen Irresein. Arch. Gen. Psychiatry 8, 65–107 (1896).
   Google Scholar
• Bergemann N, Parzer P, Runnebaum B, Resch F, Mundt C. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia. Psychol. Med. 37(10), 1427–1436 (2007).
   PubMed Web of Science ®Google Scholar
• Choi SH, Kang SB, Joe SH. Changes in premenstrual symptoms in women with schizophrenia: a prospective study. Psychosom. Med. 63(5), 822–829 (2001).
   PubMed Web of Science ®Google Scholar
• Ko YH, Joe SH, Cho W et al. Estrogen, cognitive function and negative symptoms in female schizophrenia. Neuropsychobiology 53(4), 169–175 (2006).
   PubMedGoogle Scholar
• Rubin LH, Carter CS, Drogos L, Pournajafi-Nazarloo H, Sweeney JA, Maki PM. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res. 124(1–3), 13–21 (2010).
   PubMed Web of Science ®Google Scholar
• Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr. Bull. 20(1), 203–214 (1994).
   PubMed Web of Science ®Google Scholar
• Fink G, Sumner BE, Rosie R, Grace O, Quinn JP. Estrogen control of central neurotransmission: effect on mood, mental state, and memory. Cell. Mol. Neurobiol. 16(3), 325–344 (1996).
   PubMed Web of Science ®Google Scholar
• Hughes ZA, Liu F, Marquis K et al. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr. Mol. Pharmacol. 2(3), 215–236 (2009).
   PubMedGoogle Scholar
• ter Horst GJ. Estrogen in the limbic system. Vitam. Horm. 82, 319–338 (2010).
   PubMedGoogle Scholar
• McEwen B. Estrogen actions throughout the brain. Recent Prog. Horm. Res. 57, 357–384 (2002).
   PubMedGoogle Scholar
• Prossnitz ER, Arterburn JB, Sklar LA. GPR30: a G protein-coupled receptor for estrogen. Mol. Cell. Endocrinol. 265–266, 138–142 (2007).
   PubMed Web of Science ®Google Scholar
• Cosimo Melcangi R, Garcia-Segura LM. Sex-specific therapeutic strategies based on neuroactive steroids: in search for innovative tools for neuroprotection. Horm. Behav. 57(1), 2–11 (2010).
   PubMedGoogle Scholar
• McEwen BS. Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms. J. Appl. Physiol. 91(6), 2785–2801 (2001).
   PubMed Web of Science ®Google Scholar
• Ciocca DR, Roig LM. Estrogen receptors in human nontarget tissues: biological and clinical implications. Endocr. Rev. 16(1), 35–62 (1995).
   PubMed Web of Science ®Google Scholar
• Iritani S. Neuropathology of schizophrenia: a mini review. Neuropathology 27(6), 604–608 (2007).
   PubMedGoogle Scholar
• Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr. Res. 49(1–2), 1–52 (2001).
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Pierson R. The role of the cerebellum in schizophrenia. Biol. Psychiatry 64(2), 81–88 (2008).
   PubMed Web of Science ®Google Scholar
• Fornito A, Yücel M, Pantelis C. Reconciling neuroimaging and neuropathological findings in schizophrenia and bipolar disorder. Curr. Opin. Psychiatry 22(3), 312–319 (2009).
   PubMed Web of Science ®Google Scholar
• Flashman LA, Green MF. Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment. Psychiatr. Clin. North Am. 27(1), 1–18, vii (2004).
   PubMed Web of Science ®Google Scholar
• Arevalo MA, Santos-Galindo M, Bellini MJ, Azcoitia I, Garcia-Segura LM. Actions of estrogens on glial cells: implications for neuroprotection. Biochim. Biophys. Acta 1800(10), 1106–1112 (2010).
   PubMed Web of Science ®Google Scholar
• Behl C. Estrogen can protect neurons: modes of action. J. Steroid Biochem. Mol. Biol. 83(1–5), 195–197 (2003).
   Google Scholar
• Bryant DN, Dorsa DM. Roles of estrogen receptors alpha and beta in sexually dimorphic neuroprotection against glutamate toxicity. Neuroscience 170(4), 1261–1269 (2010).
   PubMedGoogle Scholar
• Rao ML, Kölsch H. Effects of estrogen on brain development and neuroprotection – implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 28(Suppl. 2), 83–96 (2003).
   PubMed Web of Science ®Google Scholar
• Bishop J, Simpkins JW. Role of estrogens in peripheral and cerebral glucose utilization. Rev. Neurosci. 3(2), 121–138 (1992).
   PubMedGoogle Scholar
• Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog. Neurobiol. 63(1), 29–60 (2001).
   PubMed Web of Science ®Google Scholar
• Li J, Siegel M, Yuan M et al. Estrogen enhances neurogenesis and behavioral recovery after stroke. J. Cereb. Blood Flow Metab. 31(2), 413–425 (2011).
   PubMed Web of Science ®Google Scholar
• Liu M, Kelley MH, Herson PS, Hurn PD. Neuroprotection of sex steroids. Minerva Endocrinol. 35(2), 127–143 (2010).
   PubMed Web of Science ®Google Scholar
• Yang LC, Zhang QG, Zhou CF et al. Extranuclear estrogen receptors mediate the neuroprotective effects of estrogen in the rat hippocampus. PLoS ONE 5(5), e9851 (2010).
   Web of Science ®Google Scholar
• Matsumoto A. Synaptogenic action of sex steroids in developing and adult neuroendocrine brain. Psychoneuroendocrinology 16(1–3), 25–40 (1991).
   PubMed Web of Science ®Google Scholar
• Elzer JG, Muhammad S, Wintermantel TM et al. Neuronal estrogen receptor-alpha mediates neuroprotection by 17beta-estradiol. J. Cereb. Blood Flow Metab. 30(5), 935–942 (2010).
   PubMed Web of Science ®Google Scholar
• Simpkins JW, Yi KD, Yang SH, Dykens JA. Mitochondrial mechanisms of estrogen neuroprotection. Biochim. Biophys. Acta 1800(10), 1113–1120 (2010).
   PubMed Web of Science ®Google Scholar
• Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res. 34(6), 1021–1029 (2009).
   PubMed Web of Science ®Google Scholar
• Morris JA, Jordan CL, Breedlove SM. Sexual differentiation of the vertebrate nervous system. Nat. Neurosci. 7(10), 1034–1039 (2004).
   PubMed Web of Science ®Google Scholar
• Schulz KM, Molenda-Figueira HA, Sisk CL. Back to the future: the organizational – activational hypothesis adapted to puberty and adolescence. Horm. Behav. 55(5), 597–604 (2009).
   PubMed Web of Science ®Google Scholar
• González-Maeso J, Ang RL, Yuen T et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452(7183), 93–97 (2008).
   PubMed Web of Science ®Google Scholar
• Horacek J, Bubenikova-Valesova V, Kopecek M et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20(5), 389–409 (2006).
   PubMed Web of Science ®Google Scholar
• Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog. Brain Res. 172, 199–212 (2008).
   PubMed Web of Science ®Google Scholar
• Sánchez MG, Bourque M, Morissette M, Di Paolo T. Steroids–dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16(3), e43–e71 (2010).
   PubMed Web of Science ®Google Scholar
• Di Paolo T, Falardeau P. Modulation of brain and pituitary dopamine receptors by estrogens and prolactin. Prog. Neuropsychopharmacol. Biol. Psychiatry 9(5–6), 473–480 (1985).
   PubMedGoogle Scholar
• Chavez C, Hollaus M, Scarr E, Pavey G, Gogos A, van den Buuse M. The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res. 1321, 51–59 (2010).
   PubMedGoogle Scholar
• Lokuge S, Frey BN, Foster JA, Soares CN, Steiner M. The rapid effects of estrogen: a mini-review. Behav. Pharmacol. 21(5–6), 465–472 (2010).
   PubMed Web of Science ®Google Scholar
• Bethea CL, Mirkes SJ, Shively CA, Adams MR. Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biol. Psychiatry 47(6), 562–576 (2000).
   PubMed Web of Science ®Google Scholar
• Gundlah C, Lu NZ, Bethea CL. Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei. Psychopharmacology 160(3), 271–282 (2002).
   PubMed Web of Science ®Google Scholar
• Smith LJ, Henderson JA, Abell CW, Bethea CL. Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology 29(11), 2035–2045 (2004).
   PubMed Web of Science ®Google Scholar
• Osterlund MK, Halldin C, Hurd YL. Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A) receptor mRNA and binding levels in the rat brain. Synapse 35(1), 39–44 (2000).
   PubMed Web of Science ®Google Scholar
• Moses EL, Drevets WC, Smith G et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol. Psychiatry 48(8), 854–860 (2000).
   PubMed Web of Science ®Google Scholar
• Adams MM, Fink SE, Janssen WG, Shah RA, Morrison JH. Estrogen modulates synaptic N-methyl-d-aspartate receptor subunit distribution in the aged hippocampus. J. Comp. Neurol. 474(3), 419–426 (2004).
   PubMed Web of Science ®Google Scholar
• Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci. Biobehav. Rev. 32(5), 1014–1023 (2008).
   PubMed Web of Science ®Google Scholar
• Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 158(9), 1367–1377 (2001).
   PubMed Web of Science ®Google Scholar
• Häfner H, Behrens S, De Vry J, Gattaz WF. Oestradiol enhances the vulnerability threshold for schizophrenia in women by an early effect on dopaminergic neurotransmission. Evidence from an epidemiological study and from animal experiments. Eur. Arch. Psychiatry Clin. Neurosci. 241(1), 65–68 (1991).
   PubMed Web of Science ®Google Scholar
• Gogos A, Kwek P, van den Buuse M. The role of estrogen and testosterone in female rats in behavioral models of relevance to schizophrenia. Psychopharmacology 219(1), 213–224 (2012).
   PubMedGoogle Scholar
• Gogos A, Kwek P, Chavez C, van den Buuse M. Estrogen treatment blocks 8-hydroxy-2-dipropylaminotetralin- and apomorphine-induced disruptions of prepulse inhibition: involvement of dopamine D1 or D2 or serotonin 5-HT1A, 5-HT2A, or 5-HT7 receptors. J. Pharmacol. Exp. Ther. 333(1), 218–227 (2010).
   PubMedGoogle Scholar
• Arad M, Weiner I. Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis? Neuropsychopharmacology 35(7), 1570–1582 (2010).
   PubMed Web of Science ®Google Scholar
• Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 20(3), 247–252 (1996).
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Riedel A, de Castella AR et al. Estrogen – a potential treatment for schizophrenia. Schizophr. Res. 48(1), 137–144 (2001).
   PubMed Web of Science ®Google Scholar
• Kulkarni J, de Castella A, Fitzgerald PB et al. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 65(8), 955–960 (2008).
   PubMed Web of Science ®Google Scholar
• Akhondzadeh S, Nejatisafa AA, Amini H et al. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog. Neuropsychopharmacol. Biol. Psychiatry 27(6), 1007–1012 (2003).
   PubMed Web of Science ®Google Scholar
• Bergemann N, Parzer P, Jaggy S, Auler B, Mundt C, Maier-Braunleder S. Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial. Schizophr. Bull. 34(6), 1172–1181 (2008).
   PubMed Web of Science ®Google Scholar
• Ko Y-H, Joe S-H, Cho W et al. Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia. Int. J. Psychiatry Clin. Pract. 10(2), 97–104 (2006).
   PubMed Web of Science ®Google Scholar
• Usall J, Huerta-Ramos E, Iniesta R et al. Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry 72(11), 1552–1557 (2011).
   PubMed Web of Science ®Google Scholar
• Kulkarni J, Gurvich C, Lee SJ et al. Piloting the effective therapeutic dose of adjunctive selective estrogen-receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 35(8), 1142–1147 (2010).
   PubMed Web of Science ®Google Scholar
• Good KP, Kopala LC, Martzke JS et al. Hormone replacement therapy in postmenopausal women with schizophrenia: preliminary findings. Schizophr. Res. 12(3), 131 (1999).
   Google Scholar
• Chua WL, de Izquierdo SA, Kulkarni J, Mortimer A. Estrogen for schizophrenia. Cochrane Database Syst. Rev. 4, CD004719 (2005).
   Google Scholar
• Mortimer AM. Relationship between estrogen and schizophrenia. Expert Rev. Neurother. 7(1), 45–55 (2007).
   PubMedGoogle Scholar
• Bergemann N, Mundt C, Parzer P et al. Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study. Schizophr. Res. 74(2–3), 125–134 (2005).
   PubMed Web of Science ®Google Scholar
• Louzã MR, Marques AP, Elkis H, Bassitt D, Diegoli M, Gattaz WF. Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. Schizophr. Res. 66(2–3), 97–100 (2004).
   PubMed Web of Science ®Google Scholar
• Glazer WM, Naftolin F, Morgenstern H, Barnea ER, MacLusky NJ, Brenner LM. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology 10(3), 345–350 (1985).
   PubMedGoogle Scholar
• Melcangi RC, Panzica G, Garcia-Segura LM. Neuroactive steroids: focus on human brain. Neuroscience 191, 1–5 (2011).
   PubMedGoogle Scholar
• Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). Front. Neuroendocrinol. 30(1), 65–91 (2009).
   PubMed Web of Science ®Google Scholar
• Ritsner MS. The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia. Neuroscience 191, 91–100 (2011).
   PubMedGoogle Scholar
• Marx CE, Bradford DW, Hamer RM et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 191, 78–90 (2011).
   PubMed Web of Science ®Google Scholar
• Feifel D, Macdonald K, Nguyen A et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry 68(7), 678–680 (2010).
   PubMed Web of Science ®Google Scholar
• Dennis CL, Ross LE, Herxheimer A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst. Rev. 4, CD001690 (2008).
   Google Scholar
• Kretschmer E. Koürperbau und Charakter. Untersuchungen zum Konstitutionsproblem und zur Lehre von den Temperamenten. Springer, Berlin, Germany (1921).
   Google Scholar
• Maric N, Popovic V, Jasovic-Gasic M, Pilipovic N, van Os J. Cumulative exposure to estrogen and psychosis: a peak bone mass, case–control study in first-episode psychosis. Schizophr. Res. 73(2–3), 351–355 (2005).
   PubMedGoogle Scholar
• Bergemann N, Mundt C, Parzer P et al. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr. Res. 73(2–3), 357–366 (2005).
   PubMed Web of Science ®Google Scholar
• Canuso CM, Goldstein JM, Wojcik J et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 111(1), 11–20 (2002).
   PubMed Web of Science ®Google Scholar
• Huber TJ, Rollnik J, Wilhelms J, von zur Mühlen A, Emrich HM, Schneider U. Estradiol levels in psychotic disorders. Psychoneuroendocrinology 26(1), 27–35 (2001).
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am. Heart J. 150(6), 1115–1121 (2005).
   PubMed Web of Science ®Google Scholar
• Archer DF. Premature menopause increases cardiovascular risk. Climacteric 12(Suppl. 1), 26–31 (2009).
   PubMed Web of Science ®Google Scholar
• O’Donnell E, Goodman JM, Harvey PJ. Clinical review: cardiovascular consequences of ovarian disruption: a focus on functional hypothalamic amenorrhea in physically active women. J. Clin. Endocrinol. Metab. 96(12), 3638–3648 (2011).
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z et al.; Women’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290(13), 1729–1738 (2003).
   PubMed Web of Science ®Google Scholar
• Baker L, Meldrum KK, Wang M et al. The role of estrogen in cardiovascular disease. J. Surg. Res. 115(2), 325–344 (2003).
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD et al.; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289(24), 3243–3253 (2003).
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 82(5), 410–417 (2010).
   PubMed Web of Science ®Google Scholar
• Soares CN, Poitras JR, Prouty J. Effect of reproductive hormones and selective estrogen-receptor modulators on mood during menopause. Drugs Aging 20(2), 85–100 (2003).
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3), 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362(9382), 419–427 (2003).
   PubMed Web of Science ®Google Scholar
• Arevalo MA, Santos-Galindo M, Lagunas N, Azcoitia I, Garcia-Segura LM. Selective estrogen-receptor modulators as brain therapeutic agents. J. Mol. Endocrinol. 46(1), R1–R9 (2011).
   PubMed Web of Science ®Google Scholar
• DonCarlos LL, Azcoitia I, Garcia-Segura LM. Neuroprotective actions of selective estrogen-receptor modulators. Psychoneuroendocrinology 34(Suppl. 1), S113–S122 (2009).
   Google Scholar
• Littleton-Kearney MT, Ostrowski NL, Cox DA, Rossberg MI, Hurn PD. Selective estrogen-receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev. 8(3), 309–330 (2002).
   PubMedGoogle Scholar
• Cyr M, Calon F, Morissette M, Grandbois M, Di Paolo T, Callier S. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr. Pharm. Des. 6(12), 1287–1312 (2000).
   PubMed Web of Science ®Google Scholar
• Cyr M, Thibault C, Morissette M, Landry M, Di Paolo T. Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain. Neuropsychopharmacology 25(2), 242–257 (2001).
   PubMedGoogle Scholar
• Landry M, Lévesque D, Di Paolo T. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 76(4), 214–222 (2002).
   PubMed Web of Science ®Google Scholar
• Bryant HU. Selective estrogen-receptor modulators. Rev. Endocr. Metab. Disord. 3(3), 231–241 (2002).
   PubMedGoogle Scholar
• Thompson KN, Kulkarni J, Sergejew AA. Extrapyramidal symptoms and oestrogen. Acta Psychiatr. Scand. 101(2), 130–134 (2000).
   PubMed Web of Science ®Google Scholar
• Smith S, Wheeler MJ, Murray R, O’Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic – pituitary–gonadal axis. J. Clin. Psychopharmacol. 22(2), 109–114 (2002).
   PubMed Web of Science ®Google Scholar
• Melkersson KI, Hulting AL, Rane AJ. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br. J. Clin. Pharmacol. 51(4), 317–324 (2001).
   PubMed Web of Science ®Google Scholar
• Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 28(Suppl. 2), 97–108 (2003).
   PubMed Web of Science ®Google Scholar
• Tworoger SS, Hankinson SE. Prolactin and breast cancer etiology: an epidemiologic perspective. J. Mammary Gland Biol. Neoplasia 13(1), 41–53 (2008).
   PubMedGoogle Scholar
• Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology 28(Suppl. 2), 1–16 (2003).
   PubMed Web of Science ®Google Scholar
• Kulkarni J. Special issues in managing long-term mental illness in women. Int. Rev. Psychiatry 22(2), 183–190 (2010).
   PubMed Web of Science ®Google Scholar
• Bushe CJ, Bradley AJ, Wildgust HJ, Hodgson RE. Schizophrenia and breast cancer incidence: a systematic review of clinical studies. Schizophr. Res. 114(1–3), 6–16 (2009).
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 80(1), 19–32 (2005).
   PubMed Web of Science ®Google Scholar
• Haack S, Seeringer A, Thürmann PA, Becker T, Kirchheiner J. Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics 10(9), 1511–1526 (2009).
   PubMed Web of Science ®Google Scholar
• Blin O, Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. J. Clin. Psychiatry 62(Suppl. 7), 11–21 (2001).
   PubMedGoogle Scholar
• Collins P, Mosca L, Geiger MJ et al. Effects of the selective estrogen-receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 119(7), 922–930 (2009).
   PubMed Web of Science ®Google Scholar
• Pollock BG. Gender differences in psychotropic drug metabolism. Psychopharmacol. Bull. 33(2), 235–241 (1997).
   PubMed Web of Science ®Google Scholar
• Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J. Clin. Psychiatry 65(7), 932–939 (2004).
   PubMed Web of Science ®Google Scholar
• Arad M, Weiner I. Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males. Neuropsychopharmacology 35(11), 2179–2192 (2010).
   PubMedGoogle Scholar
• Kulkarni J, de Castella A, Headey B et al. Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr. Res. 125(2–3), 278–283 (2011).
   PubMed Web of Science ®Google Scholar